T1	Participants 503 556	184 patients, and all received initial infusions of Z
T2	Participants 123 211	patients with common cancers involving bone receiving intravenous bisphosphonate therapy
T3	Participants 1758 1843	Cancer patients prefer shorter bisphosphonate infusions-and at home, where practical.
